<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>K2M Group Holdings Inc (KTWO) Given “Buy” Rating at Piper Jaffray</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/k2m-group-holdings-inc-ktwo-given-buy-rating-at-piper-jaffray/</topic_url>
<topic_text>
Tweet 
K2M Group Holdings Inc (NASDAQ:KTWO) ‘s stock had its “buy” rating restated by stock analysts at Piper Jaffray in a research note issued on Monday, MarketBeat reports. 
A number of other equities analysts also recently weighed in on KTWO. Needham &amp; Company LLC cut their price target on shares of K2M Group Holdings from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, March 4th. William Blair reaffirmed an “outperform” rating on shares of K2M Group Holdings in a research note on Friday, March 4th. Zacks Investment Research downgraded shares of K2M Group Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, March 9th. Finally, JMP Securities started coverage on shares of K2M Group Holdings in a research note on Friday, April 8th. They set an “outperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.20. 
Shares of K2M Group Holdings ( NASDAQ:KTWO ) traded down 0.49% during trading on Monday, hitting $16.16. The stock had a trading volume of 44,810 shares. The firm has a 50 day moving average price of $14.51 and a 200 day moving average price of $16.50. K2M Group Holdings has a 12-month low of $11.15 and a 12-month high of $26.29. The firm’s market cap is $666.24 million. 
K2M Group Holdings (NASDAQ:KTWO) last posted its quarterly earnings results on Thursday, March 3rd. The medical device company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. During the same period in the prior year, the business earned ($0.30) EPS. The company had revenue of $54.20 million for the quarter, compared to analysts’ expectations of $55.47 million. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. On average, equities analysts expect that K2M Group Holdings will post ($0.85) earnings per share for the current fiscal year. 
Other hedge funds recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its stake in K2M Group Holdings by 37.0% in the fourth quarter. Alliancebernstein L.P. now owns 1,911,227 shares of the medical device company’s stock worth $37,728,000 after buying an additional 516,570 shares during the period. Emerald Mutual Fund Advisers Trust increased its stake in K2M Group Holdings by 22.7% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 865,821 shares of the medical device company’s stock worth $17,091,000 after buying an additional 160,237 shares during the period. Emerald Advisers Inc. PA increased its stake in K2M Group Holdings by 23.7% in the fourth quarter. Emerald Advisers Inc. PA now owns 792,955 shares of the medical device company’s stock worth $15,653,000 after buying an additional 151,720 shares during the period. Paradigm Capital Management Inc. NY increased its stake in K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock worth $3,350,000 after buying an additional 146,300 shares during the period. Finally, OppenheimerFunds Inc. increased its stake in K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock worth $17,925,000 after buying an additional 105,014 shares during the period. 
In other news, Director Carlos A. Ferrer acquired 38,942 shares of the business’s stock in a transaction that occurred on Monday, March 7th. The shares were purchased at an average cost of $12.84 per share, for a total transaction of $500,015.28. Following the transaction, the director now directly owns 39,382 shares in the company, valued at approximately $505,664.88. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website . 
K2M Group Holdings, Inc ( NASDAQ:KTWO ) is a global medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.  //www.americanbankingnews.com/2016/04/25/k2m-group-holdings-inc-ktwo-given-buy-rating-at-piper-jaffray/   K2M Group Holdings Inc   K2M Group Holdings Inc  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/k2m-group-holdings-inc-ktwo-given-buy-rating-at-piper-jaffray/</post_url>
<post_date>20160425</post_date>
<post_time>1841</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
K2M Group Holdings Inc (NASDAQ:KTWO) ‘s stock had its “buy” rating restated by stock analysts at Piper Jaffray in a research note issued on Monday, MarketBeat reports. 
A number of other equities analysts also recently weighed in on KTWO. Needham &amp; Company LLC cut their price target on shares of K2M Group Holdings from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, March 4th. William Blair reaffirmed an “outperform” rating on shares of K2M Group Holdings in a research note on Friday, March 4th. Zacks Investment Research downgraded shares of K2M Group Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, March 9th. Finally, JMP Securities started coverage on shares of K2M Group Holdings in a research note on Friday, April 8th. They set an “outperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.20. 
Shares of K2M Group Holdings ( NASDAQ:KTWO ) traded down 0.49% during trading on Monday, hitting $16.16. The stock had a trading volume of 44,810 shares. The firm has a 50 day moving average price of $14.51 and a 200 day moving average price of $16.50. K2M Group Holdings has a 12-month low of $11.15 and a 12-month high of $26.29. The firm’s market cap is $666.24 million. 
K2M Group Holdings (NASDAQ:KTWO) last posted its quarterly earnings results on Thursday, March 3rd. The medical device company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. During the same period in the prior year, the business earned ($0.30) EPS. The company had revenue of $54.20 million for the quarter, compared to analysts’ expectations of $55.47 million. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. On average, equities analysts expect that K2M Group Holdings will post ($0.85) earnings per share for the current fiscal year. 
Other hedge funds recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its stake in K2M Group Holdings by 37.0% in the fourth quarter. Alliancebernstein L.P. now owns 1,911,227 shares of the medical device company’s stock worth $37,728,000 after buying an additional 516,570 shares during the period. Emerald Mutual Fund Advisers Trust increased its stake in K2M Group Holdings by 22.7% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 865,821 shares of the medical device company’s stock worth $17,091,000 after buying an additional 160,237 shares during the period. Emerald Advisers Inc. PA increased its stake in K2M Group Holdings by 23.7% in the fourth quarter. Emerald Advisers Inc. PA now owns 792,955 shares of the medical device company’s stock worth $15,653,000 after buying an additional 151,720 shares during the period. Paradigm Capital Management Inc. NY increased its stake in K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock worth $3,350,000 after buying an additional 146,300 shares during the period. Finally, OppenheimerFunds Inc. increased its stake in K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock worth $17,925,000 after buying an additional 105,014 shares during the period. 
In other news, Director Carlos A. Ferrer acquired 38,942 shares of the business’s stock in a transaction that occurred on Monday, March 7th. The shares were purchased at an average cost of $12.84 per share, for a total transaction of $500,015.28. Following the transaction, the director now directly owns 39,382 shares in the company, valued at approximately $505,664.88. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website . 
K2M Group Holdings, Inc ( NASDAQ:KTWO ) is a global medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.  //www.americanbankingnews.com/2016/04/25/k2m-group-holdings-inc-ktwo-given-buy-rating-at-piper-jaffray/   K2M Group Holdings Inc   K2M Group Holdings Inc  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/k2m-group-holdings-inc-logo.jpg</main_image>
</document>
